4.5 Article

Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Urology & Nephrology

Apalutamide and Overall Survival in Prostate Cancer

Matthew R. Smith et al.

Summary: The study showed that apalutamide significantly extended overall survival and time to cytotoxic chemotherapy in patients with nmCRPC. Adverse events were consistent with previous reports, with rash being the most notable difference between the apalutamide and placebo groups.

EUROPEAN UROLOGY (2021)

Article Medicine, General & Internal

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

Cora N. Sternberg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medicine, General & Internal

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

Karim Fizazi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medicine, General & Internal

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Karim Fizazi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Medicine, General & Internal

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Medicine, General & Internal

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Maha Hussain et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Article Medicine, General & Internal

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

Matthew R. Smith et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Article Oncology

Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial

David F. Penson et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)